Check out Scrip’s annual ranking of Asia Pacific biopharma companies for 2024!
World View
While Japan retains its pole position as top money spinner in Asia, Chinese and Indian firms are coming up quickly. The industry also has eyes on these two countries as the BIOSECURE Act forces industry to re-evaluate worldwide supply chain and manufacturing contracts.
- • By
Industry support for a new regional regulator for Latin America and the Caribbean is cautious and experts warn that it could harm competitiveness of the region.
- • By
The emergence of China from API manufacturer to an innovation leader, fuelled by domestic investments and home-grown talent, has been one of the most remarkable trends of the last decade.
- • By
An over-reliance on out-licensing as a business model may restrict the healthy growth of South Korean biopharma firms over the longer term, a Citeline executive told a recent symposium in Seoul.
- • By
In the year since the Association of the British Pharmaceutical Industry raised the alarm about drastically dwindling clinical trial recruitment numbers in the UK, the country has taken a number of steps to try to turn things around.